NYU Langone Health psychedelic research trials
Data as of 31 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
NYU Langone Health is listed with 6 registered studies counted here, in New York, United States. By compound: 6 psilocybin. By registry status: 4 recruiting and 2 not yet recruiting. By phase: 1 early phase 1, 1 phase 1 and 4 phase 2. Reported start years run from 2023 (earliest) to 2026 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 6 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 6 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 4 | 67% |
| Not yet recruiting | 2 | 33% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 1 | 17% |
| Phase 1 | 1 | 17% |
| Phase 2 | 4 | 67% |
Registered studies
All counted studies, newest start first. Dates may be estimated, including future dates; a listed date does not confirm that a study started. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Registry dates | Compound |
|---|---|---|---|---|---|
| Psilocybin as a Novel Therapy for Residual Anhedonia | NCT07607938 | Recruiting | Phase 1 | Source start: 2026-09 (estimated) Saved start 2026-07-01 differs from reported 2026-09; the saved day is not established by this observation. Source date detailsStart: 2026-09 (precision: month; source type: ESTIMATED; estimated) Primary completion: 2030-08-01 (precision: day; source type: ESTIMATED; estimated) Study completion: 2030-09-30 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.566Z; registry revision: 2026-09-15 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Psilocybin |
| Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter | NCT07296328 | Not yet recruiting | Phase 2 | Source start: 2026-01-15 (estimated)Source date detailsStart: 2026-01-15 (precision: day; source type: ESTIMATED; estimated) Primary completion: 2027-04-01 (precision: day; source type: ESTIMATED; estimated) Study completion: 2027-04-01 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.483Z; registry revision: 2025-12-22 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Psilocybin |
| Psilocybin for Opioid Use Disorder (OUD) | NCT06796062 | Recruiting | Phase 2 | Source start: 2025-12-17 (actual)Source date detailsStart: 2025-12-17 (precision: day; source type: ACTUAL; actual) Primary completion: 2029-02 (precision: month; source type: ESTIMATED; estimated) Study completion: 2029-02 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.780Z; registry revision: 2026-01-23 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Psilocybin |
| Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD | NCT06349083 | Recruiting | Phase 2 | Source start: 2026-09-01 (estimated) Saved start 2025-08-26 differs from reported 2026-09-01; the saved day is not established by this observation. Source date detailsStart: 2026-09-01 (precision: day; source type: ESTIMATED; estimated) Primary completion: 2030-05 (precision: month; source type: ESTIMATED; estimated) Study completion: 2030-05 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.349Z; registry revision: 2026-09-02 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Psilocybin |
| Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS) | NCT06760533 | Not yet recruiting | Early Phase 1 | Source start: 2026-08 (estimated) Saved start 2025-08-01 differs from reported 2026-08; the saved day is not established by this observation. Source date detailsStart: 2026-08 (precision: month; source type: ESTIMATED; estimated) Primary completion: 2026-12 (precision: month; source type: ESTIMATED; estimated) Study completion: 2026-12 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.780Z; registry revision: 2026-03-05 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Psilocybin |
| Psilocybin Therapy in Advanced Cancer | NCT05398484 | Recruiting | Phase 2 | Source start: 2023-05-24 (actual)Source date detailsStart: 2023-05-24 (precision: day; source type: ACTUAL; actual) Primary completion: 2027-01-01 (precision: day; source type: ESTIMATED; estimated) Study completion: 2027-01-01 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:16.239Z; registry revision: 2026-10-14 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Psilocybin |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Country hub: United States